Looking back to go forward: adherence to inhaled therapy before biologic therapy in severe asthma

For decades inhaled corticosteroids have been central to the management of asthma and are proven to be effective in maintaining symptom control, reducing exacerbations and preserving quality of life through mediation of airway inflammation. However, a small minority of patients have disease which is refractory to high dose inhaled corticosteroid (ICS) therapy and require additional oral corticosteroids to achieve acceptable control of symptoms and exacerbations. Severe asthma represents less than 10% of the total asthma population [1] but is the most serious, life-affecting and costly form of the condition [2].
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Asthma and allergy Editorials Source Type: research